Module 2 - New Understanding of COPD Pathophysiology and Emerging Biologic Therapies
Pulmonary Disease0.25 AMA PRA Category 1 Credit(s) ™
December 02, 2024
December 02, 2025
Primary Audience:
Pulmonology physicians, nurse practitioners, and physician assistants
Relevant Terms:
Alarmin pathway, benralizumab, biologic therapy, blood eosinophil count, dupilumab, exacerbations, FeNO, GOLD guidelines, mepolizumab, type 2 inflammation
Surya P. Bhatt, MD, MSPH
Professor of Medicine
Division of Pulmonary, Allergy & Critical Care Medicine
University of Alabama at Birmingham
Surya Bhatt, MD, MSPH, is Professor of Medicine and Endowed Professor of Airways Disease in the Division of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham. He is the Director of the UAB Center for Lung Analytics and Imaging Research (CLAIR), and also serves as the Medical Director of the UAB Pulmonary Function Testing and Exercise Physiology Lab, and as Medical Director of the UAB center-based and Telehealth Pulmonary Rehabilitation Programs.
His primary clinical and research interests are in COPD. He leads 2 research programs: lung imaging and COPD clinical trials. His research is funded by the National Heart, Lung, and Blood Institute (NHLBI) with R01, R21, and UH3 grants. He has developed several new imaging biomarkers for COPD as well as new spirometric methods to detect airflow obstruction. He is the principal investigator of the multicenter TeleCOPD study, funded by the NHLBI. He has more than 240 peer-reviewed publications.
Dr. Bhatt has received multiple national and international awards for his research, including the Alfred Soffer Award from the American College of Chest Physicians, the UAB Dean’s Excellence Award for Research, Early Career Achievement Award from the Clinical Problems Assembly of the American Thoracic Society (ATS), the Dr. Linda Hall Innovation Award from the American Association of Cardiovascular and Pulmonary Rehabilitation, the Top Reviewer Award from the American Journal of Respiratory and Critical Care Medicine (AJRCCM) and Annals of the ATS, and most recently was elected member of the American Society of Clinical Investigation. He has authored multiple book chapters, including in Braunwald’s Heart Disease and Murray & Nadel’s Textbook of Respiratory Medicine. He serves as Associate Editor for Annals of the ATS and on the Editorial Board of the AJRCCM.
| 1. | Identify patients with COPD at increased risk of exacerbations and utilize emerging biomarkers to guide treatment decisions | 2. | Discuss mechanisms of action of novel biologics and the rationale for their use to treat COPD |
| 3. | Interpret recent data from clinical trials of biologics in the treatment of COPD |
| 1. | Identify patients with COPD at increased risk of exacerbations and utilize emerging biomarkers to guide treatment decisions |
| 2. | Discuss mechanisms of action of novel biologics and the rationale for their use to treat COPD |
| 3. | Interpret recent data from clinical trials of biologics in the treatment of COPD |
Module 2 - New Understanding of COPD Pathophysiology and Emerging Biologic Therapies
LEARNING OBJECTIVES
- Identify patients with COPD at increased risk of exacerbations and utilize emerging biomarkers to guide treatment decisions.
- Discuss mechanisms of action of novel biologics and the rationale for their use to treat COPD.
- Interpret recent data from clinical trials of biologics in the treatment of COPD.
COURSE INFORMATION
LAUNCH DATE/EXPIRATION DATE
This activity was launched on December 2, 2024 and will expire on December 2, 2025.
TARGET AUDIENCE
This educational initiative has been designed for pulmonology physicians, nurse practitioners, and physician assistants involved in the management of patients with COPD.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
COURSE FACULTY
Surya Bhatt, MD, MSPH
Professor of Medicine
Pulmonary, Allergy & Critical Care Medicine
The University of Alabama at Birmingham
Birmingham, AL
Surya Bhatt, MD, MSPH, discloses that he has served on advisory boards or as consultant for Apreo, Boehringer Ingelheim, Chiesi, Genentech, GSK, Merck, Regeneron, Sanofi, and Verona, and has received honoraria from HorizonCME, IntegrityCE, and Medscape. He has received funds paid to his institute for research from Sanofi, Regeneron, Genentech, and Nuvaira during the past 24 months.
OTHER CONTRIBUTOR/PLANNER DISCLOSURES
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
SUPPORTER ACKNOWLEDGMENT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
